What's New in Aquablation

Richard Lee, Claus Roehrborn

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Transurethral resection of the prostate (TURP) is considered the gold standard for minimally invasive treatment of lower urinary tract symptoms due to benign prostate enlargement of <80 ml. Although durable and effective, TURP carries the risk of significant side effects, including infection and bleeding, and the risk of dilutional hyponatremia. The Aquabeam system uses high-velocity water jets to robotically ablate prostatic tissue under real-time ultrasound guidance, with hemostasis achieved via a catheter balloon tamponade and a novel traction device or electrocautery. In this mini-review, we assess early clinical experience with the device. Short-term outcomes appear to be promising, with significant improvements in urinary symptoms and bother. Operative times have been roughly equivalent to those for TURP, while surgical complication rates have been low. Future studies are required to assess long-term effectiveness. Aquablation is an emerging technology that may provide a reasonable alternative to transurethral resection of the prostate for the treatment of benign prostate enlargement. Short-term outcomes appear promising, although studies with longer-term outcomes are needed to confirm the durability of the results.

Original languageEnglish (US)
JournalEuropean Urology Focus
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Transurethral Resection of Prostate
Prostate
Balloon Occlusion
Equipment and Supplies
Lower Urinary Tract Symptoms
Electrocoagulation
Hyponatremia
Traction
Operative Time
Hemostasis
Catheters
Hemorrhage
Technology
Water
Therapeutics
Infection

Keywords

  • Ablation techniques
  • Minimally invasive surgical procedures
  • Prostatic hyperplasia
  • Transurethral resection of the prostate
  • Water

ASJC Scopus subject areas

  • Urology

Cite this

What's New in Aquablation. / Lee, Richard; Roehrborn, Claus.

In: European Urology Focus, 01.01.2018.

Research output: Contribution to journalArticle

@article{ced23891cf2d4611a970e69bec4b11f9,
title = "What's New in Aquablation",
abstract = "Transurethral resection of the prostate (TURP) is considered the gold standard for minimally invasive treatment of lower urinary tract symptoms due to benign prostate enlargement of <80 ml. Although durable and effective, TURP carries the risk of significant side effects, including infection and bleeding, and the risk of dilutional hyponatremia. The Aquabeam system uses high-velocity water jets to robotically ablate prostatic tissue under real-time ultrasound guidance, with hemostasis achieved via a catheter balloon tamponade and a novel traction device or electrocautery. In this mini-review, we assess early clinical experience with the device. Short-term outcomes appear to be promising, with significant improvements in urinary symptoms and bother. Operative times have been roughly equivalent to those for TURP, while surgical complication rates have been low. Future studies are required to assess long-term effectiveness. Aquablation is an emerging technology that may provide a reasonable alternative to transurethral resection of the prostate for the treatment of benign prostate enlargement. Short-term outcomes appear promising, although studies with longer-term outcomes are needed to confirm the durability of the results.",
keywords = "Ablation techniques, Minimally invasive surgical procedures, Prostatic hyperplasia, Transurethral resection of the prostate, Water",
author = "Richard Lee and Claus Roehrborn",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.euf.2018.04.018",
language = "English (US)",
journal = "European Urology Focus",
issn = "2405-4569",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - What's New in Aquablation

AU - Lee, Richard

AU - Roehrborn, Claus

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Transurethral resection of the prostate (TURP) is considered the gold standard for minimally invasive treatment of lower urinary tract symptoms due to benign prostate enlargement of <80 ml. Although durable and effective, TURP carries the risk of significant side effects, including infection and bleeding, and the risk of dilutional hyponatremia. The Aquabeam system uses high-velocity water jets to robotically ablate prostatic tissue under real-time ultrasound guidance, with hemostasis achieved via a catheter balloon tamponade and a novel traction device or electrocautery. In this mini-review, we assess early clinical experience with the device. Short-term outcomes appear to be promising, with significant improvements in urinary symptoms and bother. Operative times have been roughly equivalent to those for TURP, while surgical complication rates have been low. Future studies are required to assess long-term effectiveness. Aquablation is an emerging technology that may provide a reasonable alternative to transurethral resection of the prostate for the treatment of benign prostate enlargement. Short-term outcomes appear promising, although studies with longer-term outcomes are needed to confirm the durability of the results.

AB - Transurethral resection of the prostate (TURP) is considered the gold standard for minimally invasive treatment of lower urinary tract symptoms due to benign prostate enlargement of <80 ml. Although durable and effective, TURP carries the risk of significant side effects, including infection and bleeding, and the risk of dilutional hyponatremia. The Aquabeam system uses high-velocity water jets to robotically ablate prostatic tissue under real-time ultrasound guidance, with hemostasis achieved via a catheter balloon tamponade and a novel traction device or electrocautery. In this mini-review, we assess early clinical experience with the device. Short-term outcomes appear to be promising, with significant improvements in urinary symptoms and bother. Operative times have been roughly equivalent to those for TURP, while surgical complication rates have been low. Future studies are required to assess long-term effectiveness. Aquablation is an emerging technology that may provide a reasonable alternative to transurethral resection of the prostate for the treatment of benign prostate enlargement. Short-term outcomes appear promising, although studies with longer-term outcomes are needed to confirm the durability of the results.

KW - Ablation techniques

KW - Minimally invasive surgical procedures

KW - Prostatic hyperplasia

KW - Transurethral resection of the prostate

KW - Water

UR - http://www.scopus.com/inward/record.url?scp=85046664109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046664109&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2018.04.018

DO - 10.1016/j.euf.2018.04.018

M3 - Article

C2 - 29748094

AN - SCOPUS:85046664109

JO - European Urology Focus

JF - European Urology Focus

SN - 2405-4569

ER -